A major new analysis suggests clopidogrel could be more effective than aspirin in protecting patients with coronary artery disease (CAD) against serious events such as heart attacks, strokes, and even death.
The study, published in The Lancet and presented at the European Society of Cardiology Congress in Madrid, reviewed seven clinical trials involving nearly 29,000 patients.
Half of the patients received clopidogrel, while the other half were given aspirin. Results showed that clopidogrel users had a 14% lower risk of cardiovascular and cerebrovascular complications, without an increased risk of major bleeding—a common concern with blood thinners.
Researchers concluded that clopidogrel may be a better option for long-term antiplatelet therapy in stable CAD patients. With its wide availability, generic formulation, and affordability, clopidogrel could see broader use in clinical practice.
Professor Bryan Williams, Chief Scientific and Medical Officer at the British Heart Foundation, noted:
“This research suggests clopidogrel might be more effective than aspirin at preventing recurrent heart attack or stroke, without a higher risk of major bleeding. These findings may influence how doctors choose treatment to protect patients from future heart problems.”